Regulatory T (T reg ) cells play a crucial role in maintaining peripheral tolerance and preventing autoimmunity. However, they also represent a major barrier to effective antitumor immunity and immunotherapy. Consequently, there has been considerable interest in developing approaches that can selectively or preferentially target T reg cells in tumors, while not impacting their capacity to maintain peripheral immune homeostasis. In this review, we describe our current understanding of the mechanisms underlying the recruitment, expansion, and suppressive activity of tumorassociated T reg cells, and discuss the approaches used and the challenges encountered in the immunotherapeutic targeting of T reg cells. In addition, we summarize the primary clinical targets and some emerging data on exciting new potential T reg cell-restricted targets. We propose that discovering and understanding mechanisms that are preferentially used by T reg cells within the tumor microenvironment will lead to strategies that selectively target T reg cell-mediated suppression of antitumor immunity while maintaining peripheral immune tolerance.
Introduction
The past two decades have witnessed a paradigm shift in tumor biology, from the reductionist dogma that tumors are masses of malignant cells that acquire certain cell-autonomous properties, to the evolving view that tumors are aberrant organs in which transformed cells along with other recruited normal cell types conspire to foster tumor growth and metastasis [1] . This has led to the concept of a tumor microenvironment composed of cells from the immune system, the tumor vasculature and lymphatics, as well as fibroblasts, pericytes, and the occasional adipocyte [2, 3] . The immune compartment of the tumor microenvironment, sometimes referred to as the 'immune contexture', has attracted extensive interest due to its importance both in the understanding of basic tumor biology and the implications for clinical applications [4] . The cellular composition of the tumor microenvironment is highly heterogeneous and includes almost all immune cell types, including CD8 + T cells, CD4 + T cells, regulatory T (T reg ) cells, macrophages, dendritic cells (DCs), natural killer (NK) cells, B cells, mast cells, and other cell types, with the relative percentages and phenotypes Abbreviations A2AR, adenosine receptor 2A; ADCC, antibody-dependent cell-mediated cytotoxicity; AML, acute myeloid leukemia; APCs, antigenpresenting cells; CTX, cyclophosphamide; DCs, dendritic cells; Foxp3, forkhead box protein 3; GITR, glucocorticoid-induced TNF receptor family-related protein; IDO, indoleamine 2,3-dioxygenase; IPEX, immune dysregulation, polyendorinopathy, enteropathy, X-linked; IS, immunoscore; mAbs, monoclonal antibodies; MDSCs, myeloid-derived suppressor cells; NK, natural killer; Nrp1, neuropilin 1; pDCs, plasmacytoid DCs; pT reg , peripherally derived T reg ; RANKL, receptor activator of nuclear receptor kappa-B ligand; TAAs, tumor-associated antigens; TAMs, tumor-associated macrophages; T eff , T effector; TNF, tumor necrosis factor; T reg , regulatory T cell; tT reg , thymus-derived CD4 varying considerably between tumor types and even between patients with the same tumor type. This complexity provides a 'fingerprint' for the tumor microenvironment and can be highly correlative with clinical outcome. This has led to the development of Immunoscore (IS), an approach used to quantify CD45RO + memory cells and cytotoxic memory (CD8 + ) T cells in the core and invasive margin of tumors as a possible prognostic indicator [5] . The IS assesses the immune infiltrate, and has been shown to provide high prognostic value for certain cancer types. For example, when compared to other clinical criterion, IS was shown to be a better predictor of disease recurrence in colorectal cancer patients following surgery [5] . From a functional perspective, one of the key features of the tumor immune contexture is its immunosuppressive environment, which underlies the basis for tumor escape from host immune destruction. While both tumor-intrinsic and -extrinsic mechanisms have been explored, it is generally accepted that T reg cells, a small subpopulation of CD4 + T cells endowed with potent suppressive capacity, play a pivotal role in inducing tumor-specific immune tolerance and will be the focus in this review.
T reg cells, characterized by the expression of the transcription factor Forkhead box protein 3 (FoxP3) [6, 7] , maintain immune homeostasis, and prevent autoimmune and chronic inflammatory diseases [8] . Mutations in the FOXP3 locus results in an early onset, fatal autoimmune, lymphoproliferative disease known as IPEX (Immune dysregulation, polyendorinopathy, enteropathy, X-linked) syndrome [9] . An analogous mutation in the murine Foxp3 locus identified in the Scurfy mouse phenocopies the human disease [9] . There are two primary T reg populations defined by the anatomical location of their development: thymus-derived CD4 +
Foxp3
+ T reg (tT reg ) cells and peripherally derived T reg (pT regs ) cells. The different anatomical origins impact the functional specificity of these two T reg -cell subsets, with tT reg cells responsible for the maintenance of peripheral tolerance thereby limiting autoimmunity and tissue pathology [6, 10] , whereas pT reg cells are thought to limit local immune pathologies at environmental boundaries (e.g. mucosal or fetus-maternal interfaces [11, 12] ). While the presence of pT reg cells in the tumor microenvironment and their functional impact is an important topic (as reviewed in [13, 14] ), for this review we will not distinguish between pT reg and tT reg cells and instead will discuss the impact of T reg cells on tumors in general.
T reg cells have been shown to infiltrate human tumors and are thought to limit antitumor immunity. Indeed, initial observations from human ovarian cancer patients revealed that elevated frequencies of T reg cells at the tumor site correlated with a poor clinical outcome [15] . However, later data gathered from a broader range of cancer types led to divergent correlations between intratumoral T reg -cell number and disease outcome. Such discrepancies may be the result of three possibilities. First, an inability to clearly distinguish between T reg -cells and activated T cells, which can express Foxp3. Second, T reg cells may either promote tumor development by limiting antitumor immunity, or limit tumor development by limiting the stromal environment required for its growth and metastases [16] . Third, T reg cells found in tumors may be heterogeneous in terms of their functional state and/or stability, which may in turn affect whether they have a positive or negative effect on tumor progression. Although the above issues warrant further study, there is a general agreement that T reg cells impact the tumor microenvironment and that targeting them therapeutically could be beneficial. However, substantial depletion of T reg -cell numbers and/or function could lead to deleterious autoimmune and inflammatory consequences. Thus, a key goal is to identify mechanisms or pathways that are selectively used and required for T reg function in the tumor microenvironment but dispensable for peripheral immune control [17] .
In this review, we will focus on the tumor-associated T reg cells from the perspective of the mechanisms underlying their enrichment in tumors and promotion of their function, stability, and survival and how they are specifically or nonspecifically targeted by current cancer therapeutics. We will also discuss current therapeutic approaches that may impact T reg function, and the challenges of developing novel targeting strategies that selectively target intratumoral T reg cells while not impacting their maintenance of peripheral immune tolerance.
Phenotype of tumor-associated T reg cells
Compared with conventional T helper cells, T reg cells exhibit a distinct transcription signature that underlies their immune suppressive activity, yet they are known to be heterogeneous both in phenotype and function (as reviewed in [18] ). It has been suggested that human T reg cells, in particular, have a higher degree of heterogeneity although this may be due in part to the difficulty in distinguishing them from activated conventional T cells that transiently upregulate Foxp3 and CD25, emphasizing the need for additional markers or approaches to identify human T reg cells. 
Mechanisms of T reg -cell enrichment within the tumor microenvironment
As a predominant immune cell type found in the tumor immune contexture, T reg cells are usually present as a higher ratio of T reg cells to T eff cells within the tumor site compared to the circulation or secondary lymphoid tissues, suggesting a tumor-directed compartmentalized redistribution, retention, and/or expansion [43] . Such enrichment could be explained by several mechanisms, including preferential tumortrafficking and retention, and the enhanced potential for T reg -cell proliferation within tumor-draining lymph nodes and tumor sites.
Preferential recruitment and retention of T reg cells to tumors
It has been hypothesized that activated T reg cells preferentially migrate to sites of inflammation via a chemotactic network, such as the chemokines/chemokine receptor system. Consistent with this notion, T regcell trafficking to tumors is triggered by a cohort of tumor-associated chemokines or hypoxia-induced factors, including CCL22, CCL17, CXCL12, CCL28, and vascular endothelial growth factor (VEGF) [44] . The CCL22/CCL17-CCR4 axis appears to be the most dominant mechanism responsible for T reg -cell recruitment to the tumor, first highlighted in human ovarian cancer [15] [47] . Tumor cells as well as myeloid cells are the primary sources of CCL22 and CCL17, both of which bind to the chemokine receptor CCR4 expressed by T reg cells. CCR4 blockade in mouse models using monoclonal antibodies (mAbs) or antagonists reduced intratumoral T reg -cell numbers and enhanced antitumor immunity [47] [48] [49] . In addition, it has been shown that the CCL5/CCR5 pathway is involved in the recruitment of T reg cells in a mouse model of pancreatic cancer [25] . Hypoxia-induced chemokine CXCL12 has also been reported to preferentially recruit T reg cells, but not CD8 + or CD4 + T eff cells, to human breast cancer, lung adenocarcinoma, and advanced cervical cancers [50] [51] [52] . Consistent with this, the CXCR4 antagonist AMD3100 has been reported to promote antitumor immunity in a mouse model of ovarian cancer [53] . CCL28, a chemokine prominently induced under hypoxic conditions in human ovarian cancer cells, was able to recruit T reg cells expressing CCR10, while overexpression of CCL28 induced accelerated orthotopic mouse ID8 ovarian tumor growth through preferential recruitment of CCR10 + T reg cells [54] . Surprisingly, it was also suggested that CCR10 + T reg cells, in addition to suppressing effector T cells, facilitated tumor vascularization via production of VEGFA, further contributing to their tumor-promoting activity. It should be noted that VEGFA also serves as a chemo-attractant exploited by tumor cells to induce T reg -cell infiltration through the surface receptor Nrp1, which is expressed on the majority of T reg but relatively few T eff cells. Interestingly, T reg -restricted deletion of Nrp1 reduced T reg -cell trafficking to tumors, thereby promoting tumor immunity and limiting tumor growth [55] . Thus, multiple components of the chemotactic network conspire to entice T reg cells into tumors and facilitate their retention.
Tumor-specific expansion of T reg cells
In addition to the preferential recruitment of T reg cells into the tumor site, increased proliferation (with limited cell death) results in increased T reg -cell expansion facilitating their dominance within the tumor microenvironment. This appears to be driven by antigen-, cytokine-, and metabolism-dependent mechanisms. An increased percentage of proliferating (Ki67 + ) T reg cells has been observed in a wide variety of tumor types, such as breast cancer and acute myeloid leukemia (AML), suggesting that T reg cells exhibit increased proliferative potential in response to tumor growth. Consistent with these observations, one study showed that T reg cells enter cell cycle much faster than conventional T cells during initial tumor emergence, as shown by the adoptive transfer of T cells into tumor-bearing mice and tracking the kinetics of cell proliferation in vivo [56] . Tumor-associated antigens (TAAs), which could be in the form of upregulated self-antigens, altered-self antigen as a consequence of post-transla-tional modifications, or neoantigens generated by mutagenic events in tumor cells, may drive the early and rapid expansion of T reg cells. Indeed, this proliferation potential was restricted to the CD44 hi activated/ memory rather than na€ ıve T reg populations further supporting a role of tumor-derived antigens. Interestingly, a recent study suggested that Aire is responsible for the thymic development of prostate antigen-specific T reg cells that were subsequently enriched in the tumor microenvironment of mice with oncogene-induced prostate cancer [57] . Lastly, antigen presentation is required for both self and nonself antigen-induced T reg -cell expansion, as T reg cells expand in an MHC class II-sufficient environment but not in MHC class II-deficient tumor-bearing mice [58] .
Cytokines, such IL-2 and TGFb, have been suggested to favor the expansion of intratumoral T reg cells over T eff cells within the tumor microenvironment. IL-2, a key cytokine that is required for T reg -cell function and homeostasis, is predominantly produced by local T eff cells within the tumor. IL-2 is used preferentially by T reg cells to facilitate their proliferation, in part due to higher expression of the IL-2 receptor, CD25. It has also been suggested that increased CD25 expression may also allow T reg cells to act as an IL-2 'sink' thereby limiting T eff cell proliferation [59] , although this has been questioned by some [60] . This mechanism may be more prominent during the early phase of tumor progression when T eff cells have not yet lost their ability to produce IL-2. Of note, high dose IL-2 infusion has been used clinically for the treatment of patients with metastatic melanoma and renal cell carcinoma with the goal of boosting antitumor T eff cells. Unfortunately, clinical efficacy was observed in only~20% of patients, which may have been due to preferential expansion of T reg cells [61, 62] , highlighting the challenges of using IL-2 in the clinic.
TGFb is a cytokine known to induce de novo pT reg conversion from conventional T cells and expand T reg cells in the periphery. Multiple cell types in the tumor microenvironment can produce TGFb, including MDSCs, immature DCs, and T reg cells. Interestingly, tumor cells can also enhance TGFb secretion by MDSCs [63] and immature DCs [64] . T reg cells can also produce TGFb to mediate the suppression of T eff cells while promoting their self-expansion in an autocrine manner [65] . Indoleamine 2,3-dioxygenase (IDO), an immunomodulatory enzyme associated with tumor tolerance that converts tryptophan (an essential amino acid) into kynurenine (an immunosuppressive metabolite), is mainly produced by intratumoral antigen presenting cells (APCs), especially plasmacytoid DCs (pDCs), and is also produced by a wide variety of tumors [66] . It has also been shown that IDO promotes the activation and expansion of T reg cells in both mouse and human tumors [67, 68] . Interestingly, it was suggested that there is a positive feedback loop between T reg -cell activity and IDO production, as T reg cells express the inhibitory receptor CTLA-4, thereby facilitating IDO production by APCs by ligating CD80/CD86 molecules. While ongoing clinical trials using IDO inhibitors for the treatment of a variety of solid tumors shows promise [69] , other factors that promote the expansion of intratumoral T reg cells may also be potential targets for cancer immunotherapy.
Mechanisms of T reg -cell suppression in tumors
The mechanisms by which T reg cells exert their immune suppressive function have been extensively studied [8] . The basic modes of T reg suppression include expression of soluble (cell-cell contact independent) or membranetethered (cell-cell contact dependent) inhibitory molecules, direct induction of cytolysis of target cells, metabolic disruption, and inhibition of DC maturation. Although the utilization of these mechanisms in the tumor microenvironment have been assessed to some extent, there are clear gaps in our understanding of which mechanisms are most important in different mouse and human tumors, and the extent to which they differ across different tumor types [70] . In addition, it has recently emerged that there are mechanisms, such as the Nrp1:Sema4a axis, that are critically important for the stability and survival of T reg cells thereby governing their impact on the tumor microenvironment [27] . Importantly, T reg cells can not only directly suppress cells within the tumor and draining lymph nodes but can also impact the tumor microenvironment in a noncell-autonomous manner by regulating the phenotype and function of other immune cell types.
Suppressive cytokines made by T reg cells
Suppressive cytokines, such as IL10, IL35, and TGFb, are secreted by T reg cells and required for their maximal suppressive function [8] . Although the suppressive function of T reg cells isolated from cancer patients can be blocked by addition of neutralizing mAbs against IL-10 or TGFb [71] , the relative importance of T regderived IL-10 and TGFb remains surprisingly obscure. IL-35, an Ebi3:p35 heterodimeric member of the IL-12 family, is an inhibitory cytokine produced by mouse and human T reg cells [72] . IL-35 contributes to the optimal suppressive activity of T reg cells and is also capable of inducing an IL-35-producing T reg -cell population from conventional T cells, called iTr35 [73] . Although it has been suggested that additional cell types and even some tumor types can produce IL-35 [74, 75] , T regs still appear to be the predominant source of IL-35. The observations in our laboratory suggest that a higher proportion of tumor-associated T reg cells recruited to tumors in the B16 mouse melanoma model express IL-35 when compared with their peripheral counterparts [76] . Interestingly, tumor growth was reduced in mice treated with an IL-35-neutralizing mAb or mice with a T reg cell-restricted deletion of Ebi3, thereby preventing IL-35 production, suggesting that T reg -derived IL-35 may be an important suppressive mechanism within the tumor microenvironment.
Direct cytolysis of target cells
T reg -mediated cytolysis of NKs and CD8 + T cells via Granzyme B and Perforin may also be a relevant mechanism within tumors. Mice deficient in Granzyme B clear both allogeneic and syngeneic tumor cell lines better than wild-type mice, which can be partially reversed by adoptive transfer of wild-type, but not Granzyme B-or Perforin-deficient T reg cells [77] . Moreover, while neither Granzyme B nor Perforin were expressed by na€ ıve T reg cells, they were expressed in 5-30% of intratumoral T reg cells, suggesting that cytolysis is utilized as an active suppressive mechanism by tumor-associated T reg cells.
Cell surface molecules on T reg cells
Intratumoral T reg cells express CD73 and CD39 that function in tandem to convert ATP into adenosine, a labile, highly suppressive molecule that binds to the adenosine receptor 2A (A 2A R) expressed on effector T cells [23] . The tumor microenvironment is known to have a high rate of cell turnover and the dying cells provide a significant source of extracellular ATP, which highlights the potential impact of A 2A Rmediated T reg suppression. However, its importance within the tumor microenvironment needs to be explored further.
Multiple inhibitory receptors, including CTLA-4, PD-1, and LAG-3, are known to be expressed on exhausted intratumoral CD8 + and CD4 + T eff cells and contribute to their functional impairment. They are also highly expressed on intratumoral T reg cells and in most cases potentiate their functions. For example, CTLA-4 [78, 79] and LAG-3 [80] facilitate interactions between T reg cells and DCs, leading to inhibition of DC maturation, which in turn limits their ability to present antigen and prime T cells. Indeed, T reg -restricted deletion of CTLA4 was shown to limit their suppressive function and thus promote tumor immunity and clearance [78] . Despite these early studies, more recent work has suggested that coinhibitory receptors expressed by T reg cells may also limit their inhibitory functions in certain settings [81, 82] . Considering the importance of coinhibitory receptors as immunotherapeutic targets in cancer, a thorough understanding of their functional impact on T reg cells will be crucial for rational drug design.
Pathways that regulate T reg -cell stability and function

Nrp1 is selectively enriched on Foxp3
+ T reg cells in comparison to na€ ıve Foxp3
À conventional T cells [14] . Recent studies have suggested that the maintenance of a suppressive microenvironment by T reg cells is substantially dependent on their lineage stability and survival, which is maintained by a novel Nrp1-Sema4a axis [27] . Although mice with a T reg cell-restricted deletion of Nrp1 do not exhibit any autoimmune or inflammatory symptoms throughout their lifespan, they are highly resistant to several transplantable tumors, including B16 melanoma and MC38 adenocarcinoma. Indeed, their resistance to tumor growth resembles that induced by T reg -cell ablation. Similar observations were obtained by treating tumor-bearing mice with an Nrp1 neutralizing mAb in vivo. The Nrp1-Sema4a axis was shown to be required for the lineage stability of intratumoral T reg cells, but not peripheral T reg cells, by limiting the activation of the serine/threonine protein kinase Akt, which would otherwise negatively regulate the activity of a key T regcell transcription factor, Foxo1. The absence of this pathway leads to reduction in the expression of certain hallmark T reg -cell signature genes (e.g., Helios), limits their survival by reduced expression of Bcl2, and upregulates expression of lineage defining transcription factors (e.g., T-bet, IRF4) and inflammatory cytokines (e.g., IFNc). In the same study, it was shown that many cell types in the tumor microenvironment express Sema4a, with over half being pDCs [83] along with a significant proportion of activated T eff cells [84] . In addition to maintaining T reg -cell lineage stability, a previous study has also shown that Nrp1 promotes the prolonged interaction between T reg cells and dendritic cells under physiological conditions [85] , which may also be mediated by Sema4a. Thus Nrp1 plays a critical role in maintaining intratumoral T regcell stability, survival, and function.
Clinical relevance of tumor-associated T reg cells
A growing number of studies have shown that CD8 + T-cell infiltration into tumors is a positive prognostic indicator [86, 87] . However, the impact of T reg cells has been more controversial. While several studies have suggested that a high density of T reg cells within the tumor correlates with a poor clinical prognosis, there have been a number of studies showing a positive clinical prognosis, highlighting the importance of deciphering the clinical significance of T reg cells further. For instance, studies in renal cell carcinoma [62] , hepatocellular [88] , and lung carcinoma [89] clearly demonstrated a poor prognosis associated with increased intratumoral T reg -cell density. In contrast, data from head and neck cancer [90] and colorectal carcinoma [91] showed that infiltration of T reg cells into the tumor correlates with improved disease outcome. Interestingly, contradicting observations do not seem to segregate between specific cancer types as both positive and negative correlations have been observed in breast and ovarian cancer (Table 1) . While technical inconsistencies among these studies have been attributed to the differences observed, this may not provide the primary explanation [92] . These apparently contradictory results may be attributed to several biological factors. First, the impact of T reg cells on tumor growth is influenced by the etiology of each tumor type. In most cases intratumoral T reg -cell accumulation is predictive of poor prognosis; however, in the cases where chronic inflammation drives tumor initiation, such as colorectal carcinoma, T regcell suppression of inflammation correlates with a favorable prognosis [32] . Second, there may be a temporal aspect to the impact of T reg cells on tumor growth in early versus more advanced lesions. Although T reg cells may play a beneficial role in con- 
Current clinical approaches targeting intratumoral T reg cells
Breaking down tumor-specific tolerance is a key step in the development of effective and durable cancer immunotherapy, with T reg cells a key target. Although several traditional anticancer drugs and immunotherapies impact intratumoral T reg cells, current and future efforts have focused on developing therapies which specifically modulate intratumoral T reg -cell number, activity, or trafficking, with several approaches exhibiting clinical benefits in a variety of murine tumor models and in human clinical trials (Fig. 1 ).
Nonspecific modulation of T reg cells by traditional anticancer drugs
Although traditional chemotherapeutic agents at their conventional, clinically effective dose are generally immunosuppressive and eliminate highly proliferating cells, it has been shown that certain drugs when used at a lower dose, over a long period of time (termed as 'metronomic chemotherapy' [97] ), can exhibit a broad spectrum of immunostimulatory effects. T reg cells were shown to be preferentially affected, in part due to the fact that they exhibited a proliferative advantage over T eff cells in most tumor microenvironments. One extensively studied example is cyclophosphamide (CTX), a frequently utilized traditional chemotherapeutic agent, which has been shown to reduce intratumoral T reg cells and concomitantly reactivate intratumoral T eff cells [98] . This effect was shown to be surprisingly durable despite a rapid rebound of peripheral T reg cells [99] , highlighting the restricted tumoral impact. Improved CTX selectivity and efficacy was observed in combination with an agonist antibody against the costimulatory receptor OX40 (CD134), as evidenced by the increased intratumoral T eff /T reg cell ratio and the regression of established B16 melanoma tumors [100] . However, the levels of circulating MDSCs in patients with early-stage breast cancer were increased [101] , suggesting the clinical efficacy of a low-dose CTX regimen could be influenced by other factors, including cancer type and stage of disease, and the differential status of individual patients. Some targeted therapies have been reported to downregulate the suppressive activity of T reg cells. The therapeutic effects of the tyrosine kinase inhibitors sunitinib and sorafenib, which have been approved by the FDA for the treatment of renal cancer carcinoma, have been reported to inhibit intratumoral T reg cells [102] [103] [104] , while another tyrosine kinase inhibitor imatinib has been suggested to inhibit T reg -cell expansion via inhibition of STAT3 and STAT5 signaling [105] . Although chemotherapeutic agents are able to limit T reg -cell function and proliferation, they are not specific to tumor-associated T reg cells and therefore are unlikely to be a long-term choice for T reg -targeted approaches.
Direct intratumoral T reg -cell depletion
Two agents for T reg -cell depletion in humans have been developed; Daclizumab (Zenapax; PDL BioPharma, Incline Village, NV, USA), a monoclonal antibody against CD25, and Denileukin Diftitox (Ontak; Eisai, Inc. Woodcliff Lake, NJ, USA), an IL-2:diphtheria toxin fusion protein. Clinical trials with Daclizumab, when combined with dendritic cell vaccinations, have reported beneficial effects in glioblastoma [106] and breast cancer patients [107] , but marginal efficacy in metastatic melanoma patients [108] . Similarly, Denileukin Diftitox, initially approved by the FDA for the treatment of T-cell lymphoma, was also effective in renal cell carcinoma patients [109] , but had a negative outcome in clinical trials with metastatic melanoma patients [110] . Such conflicting results may be due to several reasons. First, the in vivo efficiency of T reg -cell elimination was not uniform among different tumor types, partially due to variable CD25 expression [111] . Second, the timing of treatment may be a key factor impacting clinical outcome, as this may influence the extent to which beneficial effector responses, induced by concomitant vaccination, are blocked [108] . Although T reg -cell depletion could induce severe systemic inflammation, this was not observed in most studies. Instead, one recent study revealed that anti-CD25 blockade preferentially inhibited the suppressive activity and stability of T reg cells instead of inducing their elimination [107] . These findings suggested the T reg -cell depletion regimens, upon further optimization, may prove to be effective. Alternatively, it is possible that optimal intratumoral T regcell depletion using these approaches will result in systemic complications. Lastly, even if these approaches work, efficacy between different patients may be highly variable and difficult to predict.
Blocking T reg -cell trafficking into tumors
Tumor-associated T reg cells acquire a distinct pattern of chemokine receptor expression in comparison to peripheral T reg cells and conventional T cells, which may provide another layer of selectivity for targeting T reg cells in tumors. The CCR4-CCL22 pathway represents the dominant mechanism for intratumoral T regcell recruitment into multiple tumor types, thereby providing a rationale for the development of CCR4 antagonists. An anti-CCR4 antibody, which was defucosylated to enhance antibody-dependent cellmediated cytotoxicity (ADCC), to treat T-cell leukemia-lymphoma recently completed a Phase II clinical trial with promising results [49] . Initially, there were concerns that CCR4 targeting would negatively impact T eff cells as a proportion of them also express CCR4. However, several studies have suggested that anti-CCR4 treatment consistently induces strong antigen-specific intratumoral CD8 + T-cell accumulation and function rather than impacting their frequency [112] . It is possible that the positive benefits of limiting T reg cell-mediated inhibition simply override the negative impact of partial T eff -cell depletion within the tumor microenvironment. Thus, targeting differentially expressed chemokine receptors may prove efficacious.
Checkpoint blockade and immune agonists: preferential inhibition of T reg -cell function?
Therapeutic targeting of inhibitory receptors, often referred to as checkpoint blockade, has garnered significant attention and is rapidly becoming standard of care for several tumor types. In just the past 4 years, four human mAbs have been approved by the FDA that target the inhibitory receptors CTLA-4 (Ipilimumab and Tremelimumab) and PD-1 (Nivolumab and Pembrolizumab), respectively. It was initially thought that the clinical efficacy of anti-CTLA4 was mainly through the reactivation of exhausted intratumoral CD4 + and CD8 + T eff cells. It was subsequently suggested that CTLA-4 blockade may have a dual effect on both T eff and T reg cells, tipping the balance toward an effector response and triggering the tumor rejection. The clinical impact of anti-CTLA4 is supported by several observations. First, CTLA-4 is highly expressed by T reg cells and appears crucial for their suppressive function, as demonstrated by a study in which mice with a T reg cell-restricted deletion of Ctla4 displayed a fatal autoimmune pathology similar to total T reg -cell depletion [78] . Second, CTLA-4 mAbs that possess some Fcc receptor ADCC activity were shown to limit intratumoral CTLA-4 + T reg cells [113] . In support of this notion, a positive correlation between the efficacy of Ipilimumab (which has a human IgG1 isotype and thus possesses some ADCC capacity) and reduction of T reg -cell numbers has been reported in patients [114] . Furthermore, in a recent study examining the antitumor efficacy of different anti-CTLA-4 isotype variants that differ in their affinity for Fcc receptors, tumor clearance in the MC38 and CT26 mouse models was partially or completely abrogated by mutating the Fc portion thereby limiting ADCC [115] . However, the other anti-CTLA4 mAb in the clinic, Tremelimumab, has a human IgG2 isotype negating any ADCC capacity and yet exhibits comparable clinical efficacy. Thus it remains unclear to what extent T reg depletion plays a role in the mechanism of action of Ipilimumab. Taken together, these data suggest three possible interpretations. First, Ipilimumab has no T reg -depleting activity and its efficacy, like Tremelimumab, is mediated by CTLA-4 blockade that limits T reg function and facilitates CD8 and CD4 T effcell expansion. In this instance, the apparent loss of T regs may be a consequence of effector T-cell expansion which in turn limits T reg proliferation. Second, Ipilimumab does have some T reg -depleting activity but its ability to limit CTLA-4 activity on T reg and effector T cells is less than Tremelimumab such that their mean clinical efficacy is the same. Third, Ipilimumab does have some T reg -depleting activity, however this is incomplete and thus has no meaningful effect on T reg activity at the population level. Thus the mean clinical efficacy of Ipilimumab and Tremelimumab is mediated by their capacity to limit T reg function and facilitate CD8 and CD4 T eff -cell expansion. Clearly, additional studies are required to resolve this uncertainty.
Several other molecules that are preferentially expressed by T reg cells can also be targeted for functional modulation. GITR (glucocorticoid-induced TNF receptor family-related protein) is a costimulatory molecule that is constitutively expressed on T reg cells and induced in conventional T cells upon activation. In contrast to inhibitory receptors, the engagement of GITR by its ligands boosts the effector function of CD25 À conventional T cells while abrogating the suppressive activity of T reg cells, a mechanism that may be exploited to restore protective immunity against tumors [116] . Indeed, it was shown in mouse models that the administration of agonistic anti-GITR mAb provoked potent antitumor responses manifested by increased IFNc-producing CD8 + and CD4 + T eff -cell infiltration, as well as enhanced T reg -cell resistance [117] . Consistent with this, a combination of an agonist GITR mAb and a anti-CTLA-4 mAb exhibited enhanced efficacy against more advanced tumors, due to the distinct quantitative (increased number) and qualitative (enhanced activity) changes in T eff cells induced by modulating CTLA-4 and GITR signaling, respectively [118] . However, it remains unclear what the effect of this combinational treatment has on T reg number and function, warranting further study. Interestingly, another TNF receptor superfamily member, OX40, was found to 'mirror' GITR substantially in terms of expressional and functional impact on T cells, highlighting its potential as a target for immunotherapeutic development. OX40 is expressed at high levels in resting and activated T reg cells, whereas it is only induced in a transient manner on effector T cells. Similar to GITR, it acts as a costimulatory receptor for T cells, whose engagement leads to enhanced effector responses but impaired T reg cell-mediated immune suppression in vivo, as evidenced in both autoimmune and tumor settings [119, 120] . Such T reg inhibition is likely to be achieved by enhancing T regcell death selectively at their site of activation (intratumoral but not systemically), a process that can be sensitized by chemotherapy-induced tumor antigen release [100] . In light of these promising results from animal models, human antibodies against GITR and OX40 are currently in clinical trials [121] .
Concluding remarks and future directions
The immune suppressive activity of intratumoral T reg cells represents a major hurdle for effective antitumor immunity, highlighting their potential as an immunotherapeutic target. Moreover, there is considerable interest in the possible synergistic opportunities of combining T reg cell-targeted therapies with other modalities, such as immune checkpoint blockade, immune agonists, tumor-specific vaccines, radiotherapy, and chemotherapy. However, there remain several significant gaps in our knowledge and many challenges ahead.
First, a more in-depth understanding of basic T regcell biology within the tumor microenvironment is warranted. T reg cells differentially impact tumors of different etiologies, leading to complicated or even opposing clinical relevance across various cancer types. This highlights the importance of more in-depth mechanistic studies in a wide variety of human tumors. In addition, relatively little is known about the temporal requirement of T reg cells at different stages of tumor progression and metastases, and whether this differs between tumor types. This analysis would not only identify additional potential therapeutic targets but would also likely inform clinical trial design and highlight additional biomarkers that could be used to assess T reg -cell function and fate following therapeutic intervention.
Second, the techniques used to enumerate and phenotypically and functionally characterize human T reg cells will critically influence clinical trial design and monitoring. While Foxp3 is a reliable and authentic marker of T reg cells in mice, it can be limiting in certain human settings. Thus, the development of additional markers and/or approaches that can reliably identify all human T reg cells would be highly desirable. Furthermore, it would also be desirable to define markers that identify more functionally suppressive T reg -cell populations within the tumor microenvironment that could be selectively studied and targeted. For example, unlike its expression on murine T reg cells, NRP1 is barely detected on na€ ıve human peripheral T reg cells but may be upregulated on T reg cells infiltrating certain tumors [122, 123] . This raises the possibility that NRP1 + tumor-associated T reg cells are a more suppressive population and have a closer correlation with clinical outcome.
Third, while potential therapeutic benefit may be obtained from current approaches designed to transiently deplete or limit T reg cells, it is possible that this may lead to highly variable clinical observations. Thus, there is a clear need to develop more selective approaches to limit intratumoral T reg -cell function without impacting peripheral immune homeostasis. Moreover, intratumoral T regs may be a functionally heterogeneous population and thus single cell analyses, such as single cell RNA-seq, may facilitate further characterization. Going forward, it will be important to determine if there are defined subpopulations, with druggable targets, that are more critically involved in the promotion of tumor growth and/or blockade of antitumor immunity, and distinguishable for those that mediate peripheral immune homeostasis. Thus future studies aimed at developing therapies that surgically target certain tumor-promoting T reg subpopulations may be important. Based on recent observations from our laboratory, we propose that this goal is achievable and may be efficacious, with IL-35 and the Nrp1:Sema4a axis as potential options.
Fourth, the role of costimulatory and coinhibitory molecules in modulating T reg function and survival remains unclear and warrants further investigation and clarification. This is particularly important as we attempt to interpret clinical observations with checkpoint inhibitors and agonist antibodies that are in clinical trials and likely impact multiple T-cell populations.
Finally, the points raised above have focused on T reg cell-intrinsic considerations. However, tumor tolerance is established via a complex network involving multiple suppressor cell types, as well as feed forward mechanisms mediated by tumor cells to reinforce the immune suppressive tumor microenvironment. Thus, we need a greater understanding of T reg cell-extrinsic parameters. For example, MDSC, TAMs, pDCs, and other populations support the local expansion and functional modulation of T reg cells, while T reg cells in turn have a global and multifactorial impact on the tumor microenvironment. Thus, the identification of molecules or pathways promoted by tumor cells and other populations within the tumor microenvironment that lead to the modulation of T reg -cell survival and function may also provide novel immunotherapeutic targets.
Thus, while many gaps remain and the true efficacy of targeting T regs in tumors has yet to be determined, observations from both mouse models and human clinical trials and studies are extremely encouraging. 
